Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Zamuner

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Arthritis Research & Therapy|November 30, 2013
Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trialsErnest H Choy, Marina Bendit, Dana McAleer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 14, 2011
A pharmacokinetic PET study of NK₁ receptor occupancyStefano Zamuner, Eugenii A Rabiner, Sofia A Fernandes, et al.
Journal of Clinical Psychopharmacology|October 25, 2011
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorderEmiliangelo Ratti, Kevin Bellew, Paolo Bettica, et al.
British Journal of Clinical Pharmacology|January 13, 2011
Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy menMarieke Liem-Moolenaar, Mandana Rad, Stefano Zamuner, et al.
Journal of Psychopharmacology (Oxford, England)|April 5, 2014
Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approachAmir Inamdar, Emilio Merlo-Pich, Michelle Gee, et al.
Scientific Reports|October 22, 2020
Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromesAlberto A Toffano, Giacomo Chiarot, Stefano Zamuner, et al.
British Journal of Clinical Pharmacology|March 16, 2017
CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6<sup>+</sup> cells in an experimental suction blisterGerben Bouma, Stefano Zamuner, Kirsty Hicks, et al.
Journal of Psychopharmacology (Oxford, England)|November 4, 2011
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsSusan Learned, Ole Graff, Suraja Roychowdhury, et al.
Sleep|December 3, 2013
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomniaEmiliangelo Ratti, David J Carpenter, Stefano Zamuner, et al.
Science (New York, N.Y.)|October 26, 2019
Self-organization of <i>parS</i> centromeres by the ParB CTP hydrolaseYoung-Min Soh, Iain Finley Davidson, Stefano Zamuner, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Arthritis Research & Therapy|November 30, 2013
Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trialsErnest H Choy, Marina Bendit, Dana McAleer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 14, 2011
A pharmacokinetic PET study of NK₁ receptor occupancyStefano Zamuner, Eugenii A Rabiner, Sofia A Fernandes, et al.
Journal of Clinical Psychopharmacology|October 25, 2011
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorderEmiliangelo Ratti, Kevin Bellew, Paolo Bettica, et al.
British Journal of Clinical Pharmacology|January 13, 2011
Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy menMarieke Liem-Moolenaar, Mandana Rad, Stefano Zamuner, et al.
Journal of Psychopharmacology (Oxford, England)|April 5, 2014
Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approachAmir Inamdar, Emilio Merlo-Pich, Michelle Gee, et al.
Scientific Reports|October 22, 2020
Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromesAlberto A Toffano, Giacomo Chiarot, Stefano Zamuner, et al.
British Journal of Clinical Pharmacology|March 16, 2017
CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6<sup>+</sup> cells in an experimental suction blisterGerben Bouma, Stefano Zamuner, Kirsty Hicks, et al.
Journal of Psychopharmacology (Oxford, England)|November 4, 2011
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trialsSusan Learned, Ole Graff, Suraja Roychowdhury, et al.
Sleep|December 3, 2013
Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomniaEmiliangelo Ratti, David J Carpenter, Stefano Zamuner, et al.
Science (New York, N.Y.)|October 26, 2019
Self-organization of <i>parS</i> centromeres by the ParB CTP hydrolaseYoung-Min Soh, Iain Finley Davidson, Stefano Zamuner, et al.
Pageof 5